NEW YORK, November 20, 2026 — The FDA has approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, marking a new treatment option for this chronic autoimmune disease.
Understanding Generalized Myasthenia Gravis
Generalized myasthenia gravis is a long-term neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness, according to the Wikipedia page on Myasthenia gravis. The disease occurs when the immune system produces antibodies that disrupt communication between nerves and muscles at the neuromuscular junction, causing muscle weakness that worsens with activity and improves with rest.
Complement Inhibition with Cemdisiran
Cemdisiran, developed by Regeneron Pharmaceuticals and licensed from Alnylam, is a complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapy. It works by reducing production of complement component factor 5 (C5) via RNA interference, limiting terminal complement activation at the neuromuscular junction, which contributes to muscle weakness in people with gMG. This mechanism is different from traditional treatments that target acetylcholine receptors or broadly suppress the immune system.
Comparison to Acetylcholine Receptor Antibodies
The approval of cemdisiran provides a new targeted treatment option for people living with gMG, particularly those who are anti-AChR antibody-positive, which accounts for approximately 85% of gMG cases. Unlike treatments that focus on acetylcholine receptor antibodies, cemdisiran targets the complement pathway, offering a distinct approach to managing the disease. According to Regeneron, cemdisiran is the only FDA-approved gMG treatment administered subcutaneously four times a year, providing a more convenient dosing schedule compared to other treatments.
Clinical Context and Market Landscape
The clinical context for gMG treatment is evolving, with a shift towards more targeted and mechanism-based therapies. Patients should consider factors such as administration burden, mechanism durability, and long-term safety profiles when discussing treatment options with their healthcare provider.
Conclusion and Next Steps
Early findings suggest that cemdisiran offers a promising new approach to treating gMG, particularly for patients who are anti-AChR antibody-positive. The encouraging part of this development is the potential for improved patient outcomes and quality of life. However, as with any new treatment, it is crucial for patients to talk to their doctor about the benefits and risks of cemdisiran and how it may fit into their individual treatment plan.
Sources
- Myasthenia gravis
- FDA Approves Livsayis™ (cemdisiran) for Adults Living with Generalized Myasthenia Gravis | Muscular Dystrophy Association
- FDA Approves Gefurulimab for Generalized Myasthenia Gravis | NeurologyLive – Clinical Neurology News and Neurology Expert Insights
- FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis | AJMC
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
- Precision Therapies Expand Treatment Options for Generalized Myasthenia
Photo: CDC / Unsplash (Unsplash License)





